Speakers

Artur Chabowski

Artur Chabowski

has over 18 years’ experience in investment banking, where he dealt with international mergers and acquisitions, equity capital transactions in Poland and other Central and Eastern European countries. Before he created advisory firm ACADIA he had worked as a Director in KPMG, a Director and a Management Board Member in ABN AMRO Corporate Finance, a Deputy Director in CAIB Financial Advisers S.A. and as a councillor in the Ministry of Ownership Transformation. At present, he is a member of various supervisory boards and co-founder of Cambridge-PYTHON Foundation. He graduated from Warsaw University of Technology, and studied at Princeton University.


Marcin Szumowski

Marcin Szumowski

has graduated from the University of Illinois with an MSc and PhD degrees (in atmospheric physics) and also earned an MBA (in entrepreneurship and international finance). Following a successful research career in the United States, since 2000 he has been involved in technology transfer and set up several start-up companies, including a 2005 high technology start-up (www.medicalgorithmics.com). During the period of 2005-2009 as the president and CEO of Medicalgorithmics he secured over 4 million PLN in private equity investment and nearly 4 million in matching public funds. He was also responsible for its business development during advanced medical diagnostics R&D, with two products cleared for marketing in Europe (CE mark, 2008, 2009) and USA (FDA 510k approval, 2009). In 2010 Medicalgorithmics SA recorded a 1.6 million net profit based on 5 million PLN revenue, with over 40% of its sales in the United States. Dr. Szumowski has been involved in preparation and management of more than 40 R&D and investment projects with a combined budget of over 200 million euro. Currently he is responsible for establishing a technology transfer platform within a bio-tech-med cluster (BTM Mazovia). BTM Mazovia Cluster is forming around a 100 million euro Centre for Preclinical Research and Technology (CePT) project involving three largest Warsaw universities and seven Polish Academy of Science institutes. It also brings together several biotech and biomed companies, VC and seed funds in partnership with the City of Warsaw.


Martin Fusek

Martin Fusek

In 1983 he received Master degree in Organic Chemistry at the ICT, Prague and in 1988 finished his PhD studies in the field of Biochemistry at the IOCB, Prague. During 1988 – 1994 he worked as post-doctoral fellow at OMRF(USA) and EMBL (Germany). From 1995 he held various managerial positions in company Sigma-Aldrich and in company Merck. Since 1995 he lectures at the Institute of Chemical Technology in Prague. From 2007 he has focused on the area of tech transfer. From 2009 he is the CEO of the IOCB TTO (www.iocb-tto.cz), a company providing tech transfer services to Institute of Organic Chemistry and Biochemistry, Czech Acad. Sci. and he is director of a cluster MedChemBio (www.medchembio.cz).


Piotr Lassota

Piotr Lassota

Having graduated from the Chemistry Faculty at the University of Warsaw, he then received his Ph.D. from the Polish Academy of Sciences. During his studies he spent a year as a visiting student at the Yale Medical University and then did his postdoctoral training at the Sloan – Kettering Institute for Cancer Research in New York, where he later worked as a researcher. He is author of over thirty publications and received numerous scientific and business awards. He also obtained 9 patents mainly in the area of oncology.

He developed his career in the pharmaceutical business in the USA, working in the research and development areas of companies such as American Cyanamid, Wyeth and Novartis. In Novartis he was the Executive Director of the US Oncology Pharmacology Unit and Executive Member of the Oncology Therapeutic Area Board. Most recently, the Divisional Vice President, Imaging Biology & Oncology at Caliper Life Sciences.

In Polpharma he is responsible for scientific supervision and development project management for biotechnology based products.


Robert Rzemiński

Robert Rzemiński

Member of the Board in MCI.BioVentures Sp. z o.o. Has over 14 years experience in Pharma Business. Since 2000 Member of the Management Board –Research & Development Director of JELFA S.A. first stock exchange pharmaceutical company in Poland. Since 2005 Member of the Board and President of Scientific Information Centre OINPHARMA. He graduated Wrocław University Chemistry faculty and post-graduate studies at WirtchaftsföderungInstitut in Vienna and GSBA in Zurich. Currently he is Member of the Boards of portfolio companies: Genomed, Biotech Varsovia Pharma and 4med.


Graeme Martin

Graeme Martin

is President and CEO of Takeda Ventures, Inc. (TVI) with day-to-day responsibility for operations. With more than 30 years of pharmaceutical R&D experience in the Pharmaceutical and Biopharmaceutical industry (Wellcome; GlaxoWellcome: Hoffman La Roche; Telik), he joined Takeda in 2003 and has been instrumental in building the Company’s strategic venture operations based in Palo Alto, California. Dr. Martin received his Bachelor of Science degree in Pharmacology from the University of Bath, and his doctorate from University College, London, UK.


Graziano Seghezzi

Graziano Seghezzi

is a Partner of Sofinnova and he invests in life sciences. He joined the firm in 2006. Graziano invested in Creabilis Therapeutics (Italy), a specialty dermatology company developing products in multiple clinical areas such as psoriasis and atopic dermatitis; Crescendo Biologics (UK), a seed-stage company targeting the application of highly innovative antibody fragment technologies to the development of new therapeutics; GlycoVaxyn (Switzerland), a biotechnology company dedicated to the development of novel vaccines; and Omthera (USA), specialized in cardiovascular disorders with a best-in-class omega-3 drug. Graziano is a board member of each company.

Prior to joining Sofinnova Partners’ Paris-based team, Graziano was principal at Index Ventures in Geneva, Switzerland, where he invested in biotechnology and biopharmaceuticals companies. Before this, he worked for Sofinnova Partners, identifying new investment opportunities in Italian pharmaceutical and medical device companies out of Milan, Italy. Graziano began his career as a biomedical researcher at New York University’s School of Medicine, where he gained five years of hands-on experience studying the molecular mechanism of angiogenesis in oncology and cardiovascular diseases.

Graziano has a degree in genetics and microbiology from the University of Pavia (Italy) and an MBA from the RSM, Erasmus University (Netherlands).


Wojciech Przybyś

Wojciech Przybyś

MD graduated from Warsaw Medical School in 1989. He then worked for 5 years as a practising physician in the Department of Internal Medicine & Diabetology at Warsaw Medical School during which time he was accredited in Internal Medicine. He has authored a number of publications in the field of diabetology, lipid disorders and clinical research.Wojciech joined Quintiles in 1996 and occupied several positions of increasing responsibility. He held the position of General Manager Quintiles Poland from 2000 till 2011. Currently he serves in position of regional Vice President Clinical Operations covering Poland, Russia, Ukraine, Latvia, Lithuania, Estonia, Israel, Serbia, Croatia, Belarus and CIS countries.


Sander van Deventer

Sander van Deventer

is a General Partner at Forbion Capital Partners, Professor of Translational Gastroenterology Leiden University Medical Center and Chairman of the Scientific Advisory Board of the Dutch Arthritis Foundation. He is a member of the Boards of Argos Therapeutics, Amsterdam Molecular Therapeutics, Cardoz ad Hookipa.

Sander van Deventer received his medical degree and doctorate of philosophy from the University of Amsterdam, and following board certification in internal medicine and gastroenterology he worked as a scientist in the Laboratory for Medical Biochemistry, Rockefeller University, New York. It was here that TNF was discovered as a proinflammatory cytokine and he applied this knowledge to first administer an anti-TNF monoclonal antibody (later registered as Remicade®) to patients with Crohn’s disease. This was followed by a series of other immunomodulatory interventions, targeting cytokines, cytokine receptors, T cells and signal transduction pathways, using small molecules, antibodies, peptides, proteins and antisense DNA technologies. In 1995 he became director of the laboratory for Experimental Internal Medicine at the Academic Medical Center in Amsterdam, and continued to work on therapeutic signal transduction inhibition, gene therapy, and (genetically engineered) probiotics. In 1998 he co-founded Amsterdam Molecular Therapeutics (AMT), a gene therapy company that develops AAV-based gene therapy products. He subsequently was CSO and CEO of AMT which is listed at Euronext and has filed its first product, Glybera™, for market authorization with the EMEA. From 2001 until 2004, he chaired the Department of Gastroenterology and Hepatology at the Academic Medical Center in Amsterdam. He has authored more than 80 book chapters, 380 peer review scientific papers, organized several large international scientific conferences, and supervised more than 40 PhD students.


Marcell Veidner

Marcell Veidner

Founder and managing partner of Bionity R&D Investment Advisors, a Budapest-based consulting firm focusing on Life Sciences private financing and business development. Before, he was director of CEE activities at PCA Capital Advisors (Frankfurt). Previously, he was heading the department of High Tech sectors at the Hungarian Investment and Trade Development Agency. He is Board Member of the Hungarian Biotechnology Association and member of the SME Platform of EuropaBio.He graduated at biotech focused MBA program of IE Business School. He obtained diploma in business administration at the French language program of Budapest University of Economic Science with major in entrepreneurship, and his Master degree in “European Studies” at the same institution.


Paweł Węgrzyn

Paweł Węgrzyn

Associate Professor of Jagiellonian University

member of Faculty of Physics, Astronomy and Computer Science

head of Department of Games Technology

director of Postgraduate Information Society Studies

The director of European Academy of Games (ega.org.pl)

The chairman of board of partners for LifeScience Cluster (www.lifescience.pl)

A member of City Council of Kraków, chairman of Commission of Development and Innovation


Emma Palmer Foster

Emma Palmer Foster

Emma Palmer Foster is a consultant with almost 20 years’ experience in the European pharmaceutical and biotechnology sector. She established EJ Palmer Consulting in 2007, following roles in investment banking, financial communications and investor relations, journalism and technology transfer. This includes eight years in sell-side equities research and corporate finance, where she was involved in several IPOs and M&A transactions. EJ Palmer Consulting advises companies on corporate and financial strategy, IR and communications, and works with clients in a range of areas, including Board roles.

Emma has an MA in Biochemistry from the University of Oxford and an MBA from the University of Durham. She is a Trustee of the mental health charity MPF Counselling, a Visiting Fellow at Durham Business School, a member of the UK Investor Relations Society (holding its Certificate in IR), and an Associate Member of the Chartered Institute of Public Relations.


Jonathan Hepple

Jonathan Hepple

Jonathan Hepple is an experienced healthcare investor and is a Partner of Seroba Kernel Life Sciences Limited, currently investing a €75M European healthcare venture fund, and also a Partner of Rosetta Capital Limited, a secondary venture fund manager.Jonathan is based in Oxford (UK) and he sits on the board of Covagen AG (Switzerland) and also manages investments in Tranzyme (USA), GeminX (acquired by Cephalon in 2011) and Zealand Pharma (Denmark).Jonathan was a co-founder in 2001 of BioScience Managers Ltd (BML), a London-based advisory and private equity firm focused on the life sector. At BML, Jonathan was responsible for the origination and execution of numerous corporate advisory transactions for biotechnology and medical device companies. Since 2006, BML (re-named Rosetta Capital Ltd) has focused on acquiring portfolios of healthcare investments through secondary transactions. Jonathan has worked with Seroba on venture investments since 2003.Prior to founding BML, Jonathan was a member of the healthcare investment team at Rothschilds and was responsible for the management of Biotechnology Investments Limited (“BIL”) and the International Biotechnology Trust (“IBT”). During his tenure at Rothschilds from 1998 until 2001, the BIL NAV grew to $600 million and IBT’s NAV grew to over £350 million. Prior to his PhD, Jonathan spent a year conducting research at British Biotechnology plc.

Jonathan received a PhD from Cambridge University for cancer research in 1997 and a BA from Oxford University in 1992.


Oliver Murphy

Oliver Murphy

Partner Transaction Advisory ServicesOliver is a graduate of the University of Manchester in Economics and Government. He speaks fluent Polish.

Oliver has has a wide range of corporate finance, due diligence and restructuring and integration experience within both the UK and Poland and specialises in cross-border transaction support engagements comprising large multi-disciplinary, multinational teams.


Paweł Błachno

Paweł Błachno

graduate of the University of Economics in Krakow and Stockholm University. He gained experience in financial and consulting institutions (Penetrator Brokerage House – currently TRIGON and POLINVEST). Since 2004 Chairman of the Jagiellonian Centre of Innovation, where he is responsible for the overall development of the institution and the global strategy of the Jagiellonian Centre of Innovation Group. Author of the „Jagiellonian commercialization model” actively engaged in the establishment and supervision of the portfolio companies. He acquires extensive experience in developing and implementing business models, as well as managing innovative projects. At the stage of preceding the formation of the company, he draw up the terms of cooperation with entrepreneurs and leads the negotiation process. Supervises all portfolio companies.


Michał Kostka

Michał Kostka

He received Masters Degree of Veterinary Sciences at University of Veterinary and Pharmaceutical Sciences in Brno in 1998. He began working for PLIVA- Lachema a.s, Brno (later PLIVA d.d. Zagreb, Croatia) in R&D of pharmaceutical products and active pharmaceutical ingredients. From 2004 he worked for South Moravian Innovation Centre/JIC (Czech Republic) holding various managerial positions including Chief Operating Officer/Life Sciences Sector Manager. In 2010 he joined St. Anne’s University Hospital Brno – International Clinical Research Center (FNUSA-ICRC, Brno, Czech Republic) as ICRC Vice-Chair for R&D (www.fnusa-icrc.org/cs/). FNUSA-ICRC is an innovative science and research center and a top-quality public healthcare center focusing on prevention, early detection and cure primarily of cardiovascular and neurological diseases. FNUSA-ICRC is based on almost ten years of successful cooperation between St. Anne´s University Hospital in Brno and the Mayo Clinic in Rochester, Minnesota (USA).


Simon Kerr

Simon Kerr

Director of Healthcare Ventures at Imperial Innovations, joined the Group in September 2008. Having worked initially in marketing and business development roles in GlaxoWellcomeplc, Simon moved into the biotechnology sector during the mid-90s. He has extensive experience of emerging bioscience businesses, has held board-level positions in nine unlisted companies and has led over 35 licensing, financing and M&A transactions. Prior to joining Imperial Innovations, he was Commercial Director of CeNeS Pharmaceuticals until its acquisition by Paion AG.


Martin Oxley

Martin Oxley

is Country Head of UK Trade and Investment at the British Embassy in Warsaw. Prior to that he was CEO of the BPCC which under his leadership grew to be the leading international business networking organization in Poland. Over the course of the last 15 years he has held CEO and Board positions in the market leading global and regional pharmaceutical companies in Central Europe. He retains a strong interest in healthcare, life sciences and enterprise. He serves on the advisory boards of a number of youth enterprise networks. He is a recognized international expert and speaker on Poland.


Emil Stepien

Emil Stepien

has been associated with „New Connect”, and the current development platform for financing the SME sector, from its inception. He is also responsible for the development of „Catalyst” which is an organised trading platform for private and local government debt instruments.


Krzysztof Kucharczyk

Krzysztof Kucharczyk

Education

Msc in the Solid State Physic from Gdansk Technical University in 1984, Phd in Molecular Biology at the Gdansk University at Biochemistry Department in 1992

Training in Vienna University at Microbiology and Molecular Biology Department in years 1991-94. Management Study at the Gdansk University in 1995-6. Marketing Management course at McGill University in Montreal in 2004.Professional experience In 1994 founder and CEO of the “ Kucharczyk Techniki Elektroforetyczne“ company which is developing, producing and selling laboratory equipment and kits for Life Sciences market

After 2000 co-founder of two other companies in the field of molecular diagnostic and drug discovery. In 2002-04 expert of IAEA/FAO in the field of molecular diagnostic.In 2001 inventor of the Multitemperature SSCP genotyping method. Co-author of several other analytical and diagnostic patents applications in years 2002-09Employment

until now : CEO of BioVectis c/o Kucharczyk Techniki Elektroforetyczne Spzoo , Warsaw , Poland


Piotr Czapski

Piotr Czapski

Partner leading EQT Partners office in Warsaw and EQT’s operations in the CEE countries since September 2008.

At the beginning of his professional career, after completion of PhD, Piotr Czapski joined the Chrysler Corporations as a Research Engineer. Returning to Poland he joined McKinsey & Co. where he became a Partner and led McKinsey’s Business Technology Practice in Eastern Europe. In the last 3.5 years before joining EQT he was a Management Board Member of Netia S.A. which is the largest alternative telecom operator in Poland. In his role as a board member he was Head of Strategy and Business Development, responsible also for M&A activities.

Piotr Czapski is responsible for the acquisition of the world’s leading manufacturer of safety and personal lancets for capillary blood sampling: HTL-Strefa S.A by EQT in 2009. Currently he holds a position of the Supervisory Board Member at HTL-Strefa and at Bulgarian cable TV operator Blizoo.

Education: PhD in Electrical Engineering from Washington University, USA


Peter Neubeck

Peter Neubeck

joined the Life Science practice in 2008 as Senior Associate, based in Munich. He is a Principal at TVM Capital in Munich and as such involved in deal origination and the evaluation of new investments, as well as research and support for existing portfolio companies with an emphasis on clinical development stage to commercial stage investments, including virtual asset development type investments (‘Project-Focused-Companies’)

Prior to joining TVM Capital, he worked at Novartis Pharma as Global Project Leader for the Cardiovascular & Metabolism Business Franchise, and was responsible for the life cycle strategy and development of the novel potential blockbuster antihypertensive Rasilez®/Tekturna® , including the recent FDA approval of the first fixed dose combination Tekturna HCT®. Prior to this role he worked as manager in the Pharma Strategic Planning Group focusing on the global disease area strategy of Novartis.

He has completed his medical studies at Ludwig-Maximilians-University München and Harvard Medical School and holds a doctoral degree for his work in non-invasive cardiovascular imaging using electron beam tomography. After pursuing postgraduate training in neurology and internal medicine in Munich, the Cleveland Clinic and Beth Israel Deaconess Medical Center, he obtained an MBA at INSEAD and worked at McKinsey & Company’s Zurich office, serving several of the top pharmaceutical companies in turnaround and growth projects.


Simon Wallwork

Simon Wallwork

is based in Semple Fraser’s Manchester office is Head of the Semple Fraser Life Sciences Team.

With over 20 years experience advising on acquisitions, disposals, private equity and public market transactions, for a wide variety of clients including public and private companies, banks, venture capital funds and partnerships, Simon has advised on a significant number of cross border transactions and listings on international stock markets.

He is rated as a Leader in his Field by Chambers directory and described as “effective and thorough” by the Legal 500 (both directories independently review all the UK’s leading law firms).

Simon has been working within the Life Sciences sector for over 16 years and has advised on a large number of transactions over that period. His clients include Lectus Therapeutics Limited, Senexis Limited, Phagenesis Limited, London Genetics Limited, Intellihep Limited, NeuroSolutions Limited, Intercytex Limited, Curapel Limited, Imagen Biotech Limited.


Leszek Grabarczyk

Leszek Grabarczyk

Since April 2011 Deputy Director of the National Centre for Research and Development – reshaped governmental agency playing the main role in funding applied research and supporting commercialisation of research results.

January 2009 – March 2011: director of the Department for Research Applications and Innovation, Ministry of Science and Higher Education, Warsaw (main responsibilities: funding of projects and infrastructures for R&D within operational programmes Innovative Economy and Human Capital, elaboration and implementation of other programmes supporting innovation, coordination and monitoring of activities of other institutions engaged in support of R&D and innovation).

July 2007 – December 2008: deputy director of the National Centre for Research and Development – NCRD (governmental agency funding R&D, established 1 July 2007). 2004-2007: in the Polish Ministry of Science and Higher Education, Department of Science Strategy and Development; engaged inter alia in preparation of legal framework for NCRD, operational programmes Innovative Economy and Human Capital, elaboration and implementation of the largest governmental programme funding R&D and innovative activities – “Technology Initiative”.

Graduated from the National School of Public Administration, Warsaw.


Jarosław Dastych

Jarosław Dastych

Head of the Laboratory of Cellular Immunology, Institute of Medical Biology of PAS in Lodz. Founder and CEO of Proteon Pharmaceuticals. Jarosław Dastych has expertise in conducting scientific research in the field of biotechnology and implementing their results in practice. He has successfully managed six Polish and international research and technology projects with a total value exceeding 7 mln PLN, including coordination of the multicenter Research and Technology Development Project of the European Commission in the 5th EU framework Program. He is an author of over 30 publications published in international journals and co-author of 3 international patents in the field of biotechnology.


Mikołaj Gurdała

Mikołaj Gurdała

sociologist, translator, manager of social and innovative projects, coach.

Currently working with the Medical University of Lodz as Director of Strategies and Analysis Office responsible for strategic and innovation development.

CEO of Flavoopharma sp. z o.o., Member of Board of Foundation for Medical University of Lodz.

Expert in European and structural funds. For 5 years he focuses on the social economy co-creating and implementing projects related to social enterprises. He advised operators of the social economy, trained NGOs and co-created local partnerships for the social economy in Lodz region. He participated in number of projects concerning exchange of good practices in the field of social economy with organizations from France, Italy, Finland, Germany, Austria, Spain, Great Britain, Serbia and Republic of Moldova. He participated in working out standarts for creating and providing conuselling services for social enterprises in the Lodz region, especially social cooperatives.


Łukasz Kutrzeba

Łukasz Kutrzeba

has graduated from the University of Mississippi, with a PhD degree in pharmaceutical sciences, with a special emphasis on drug discovery in the area of natural products. We worked with psychoactive compounds as potential drug candidates for treatment of depression and drug abuse. In 2009 he has joined JCI Venture seed capital fund as a technology broker, being involved in data mining, project evaluation, and market research. Since 2011 he has held a position as the CEO of Hependo, a drug discovery company. Dr Kutrzeba holds also MSc degrees in Biology, and in Environmental Chemistry


Paweł Przewięźlikowski

Paweł Przewięźlikowski

co-founded Selvita in 2007 and is the Chief Executive Officer of the company. Before Selvita he spent 12 years managing high technology companies, meeting customers’ expectations and creating significant shareholder value. From 1994 to 2007 he worked at ComArch – a Polish information technology company. As board member of the company since 1996, he took part in the organic transformation of a university spin-off to the largest IT company in Poland, employing over 2 700 people. During his time at ComArch in 1999-2000 he was also the co-founder and the first CEO of Interia.pl, the third largest portal in Poland. He is also the Chief Executive of BioCentrum, Selvita’s daughter company.


Roland Kozlowski

Roland Kozlowski

received a first class honours degree from the University of Bath and a PhD from the University of Cambridge. He is a bioentrepreneur who has worked in the industry since the mid 1990s. Roland has held a number of operational roles including: Chief Executive Officer and a founder of Lectus Therapeutics Limited, Chief Executive Officer and co-founder of Sense Proteomic Limited, which he sold to Procognia Limited in 2002. In the mid 1990s Roland worked with Oxford Molecular PLC on their cornerstone deal he negotiated with Yamanouchi Pharmaceutical Co., Ltd. During his career Roland has gained considerable transactional experience ranging from company sale, purchase, financing and in- and out-licensing. In the past Roland ran a Research Group at the University of Oxford and published in the field of ion channel physiology and pharmacology. He now maintains an academic link through a Visiting Industrial Professorship at Bristol University. Roland is a non-executive director of London Genetics which operates in the personalised medicine space and has served on the main board of the Bio Industry Association in the UK. He is also President BTM Mazowsze Sp. z o. o. a company set up to commercialize innovation emerging from the leading life science research institutions in Warsaw.


Juha Vapaavuori

Juha Vapaavuori

Juha Vapaavuori is a Senior Lead at Sitra the Finnish Innovation Fund. Sitra is forward thinking organization which anticipates social change and its effect on people. Sitra’s activities promote new operating models which stimulate business that aim towards a sustainable well-being. As a public fund, Sitra report directly to the Finnish Parliament